Metotrexato Wyeth (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. Without tetrahydrofolate, cells cannot synthesize purines and thymidylate, leading to reduced DNA, RNA and protein production. This effect is most pronounced in rapidly dividing cells and activated immune cells, resulting in cytotoxic and immunosuppressive actions.

The specific dose of Metotrexato Wyeth is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Dosing regimens vary widely between autoimmune indications and oncologic protocols, and the prescriber will tailor the schedule to achieve optimal therapeutic effect while minimizing risk.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and loss. Women of child‑bearing potential must use effective contraception. Breastfeeding is also not recommended because methotrexate can be excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and necessary import documentation.

Methotrexate is a folate antagonist, whereas other antimetabolites such as 5‑fluorouracil target thymidylate synthase, and cytarabine interferes with DNA polymerase. Methotrexate’s broad utility across autoimmune and oncologic diseases, combined with its oral and injectable forms, distinguishes it from agents that are typically limited to specific cancer protocols.

Metotrexato Wyeth should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not store at room temperature for extended periods, as stability may be compromised.

The product is supplied as a sterile solution for intramuscular, intrathecal or intravenous injection. Administration technique, site selection and infusion rate are determined by the treating physician and nursing staff, following institutional protocols and ensuring aseptic conditions to minimize infection risk.

Serious risks include severe liver toxicity, pulmonary fibrosis, bone‑marrow failure leading to pancytopenia, acute renal failure, life‑threatening infections due to immunosuppression, and anaphylactic reactions. Patients should be monitored regularly for signs of organ dysfunction and instructed to report any unusual symptoms promptly.

Methotrexate is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, significant renal impairment, and those with known hypersensitivity to methotrexate or any component of the formulation. Clinicians must evaluate each patient’s medical history before initiating therapy.